Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1999 Feb;58(2):79–84. doi: 10.1136/ard.58.2.79

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

C Haagsma 1, H Blom 1, P L C M van Riel 1, H van't 1, B Giesendorf 1, D van Oppenraaij-Em 1, L B A van de Putte 1
PMCID: PMC1752831  PMID: 10343521

Abstract

OBJECTIVE—To study the influence of sulphasalazine (SSZ), methotrexate (MTX), and the combination (COMBI) of both on plasma homocysteine and to study the relation between plasma homocysteine and their clinical effects.
METHODS—105 patients with early rheumatoid arthritis (RA) were randomised between SSZ (2-3 g/day), MTX (7.5-15 mg/week), and the COMBI (same dose range) and evaluated double blindly during 52 weeks. Plasma homocysteine, serum folate concentrations, and vitamin B12 were measured. The influence of the C677T mutation of the enzyme methylenetetrahydrofolatereductase (MTHFR) gene was analysed.
RESULTS—A slight trend towards increased efficacy and an increased occurrence of minor gastrointestinal toxicity was present in the COMBI group, no differences existed clinically between SSZ and MTX. Only a slight and temporary increase in plasma homocysteine was found in the SSZ group, in contrast with the persistent rise in the MTX group and the even greater increase in the COMBI patients. Patients homozygous for the mutation in the MTHFR gene had significantly higher baseline homocysteine, heterozygous MTHFR genotype induced a significantly higher plasma homocysteine at week 52 compared with no mutation. No correlation was found between clinical efficacy variables and homocysteine. Patients with gastrointestinal toxicity had a significantly greater increase in homocysteine.
CONCLUSION—A persistent increase in plasma homocysteine concentrations was observed in patients treated with MTX alone and more pronounced in combination with SSZ, in contrast with SSZ alone. An increase in plasma homocysteine is related to the C677T mutation in MTHFR. A relation in the change in homocysteine concentrations with (gastrointestinal) toxicity was found, no relation with clinical efficacy existed.

 Keywords: homocysteine; methotrexate; sulphasalazine; arthritis

Full Text

The Full Text of this article is available as a PDF (134.7 KB).

Figure 1  .

Figure 1  

Open in a new tab

Folate metabolism. DHF: dihydrofolate, THF: tetrahydrofolate, 5',10-'CH2-THF: methylene-THF, 5'-CH3-THF: methyl-THF, MTHFR: methylenetetrahydrofolate reductase, MS: methionine synthase, BHMT: betaine-homocysteine methyl transferase, B12: vitamin B12.

Figure 2  .

Figure 2  

Open in a new tab

Plasma homocysteine compared with time. SSZ: sulphasalazine, MTX: methotrexate, COMBI : SSZ + MTX.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bannwarth B., Labat L., Moride Y., Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs. 1994 Jan;47(1):25–50. doi: 10.2165/00003495-199447010-00003. [DOI] [PubMed] [Google Scholar]
  2. Bird H. A. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Br J Rheumatol. 1995 Nov;34 (Suppl 2):16–19. [PubMed] [Google Scholar]
  3. Buckley L. M., Vacek P. M., Cooper S. M. Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990 Sep;17(9):1158–1161. [PubMed] [Google Scholar]
  4. Chabner B. A., Allegra C. J., Curt G. A., Clendeninn N. J., Baram J., Koizumi S., Drake J. C., Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep;76(3):907–912. doi: 10.1172/JCI112088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cronstein B. N. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996 Dec;39(12):1951–1960. doi: 10.1002/art.1780391203. [DOI] [PubMed] [Google Scholar]
  6. Felson D. T., Anderson J. J., Meenan R. F. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 1992 Oct;35(10):1117–1125. doi: 10.1002/art.1780351003. [DOI] [PubMed] [Google Scholar]
  7. Franklin J. L., Rosenberg H. H. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). Gastroenterology. 1973 Apr;64(4):517–525. [PubMed] [Google Scholar]
  8. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J., den Heijer M., Kluijtmans L. A., van den Heuvel L. P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–113. doi: 10.1038/ng0595-111. [DOI] [PubMed] [Google Scholar]
  9. Grindulis K. A., McConkey B. Does sulphasalazine cause folate deficiency in rheumatoid arthritis? Scand J Rheumatol. 1985;14(3):265–270. doi: 10.3109/03009748509100404. [DOI] [PubMed] [Google Scholar]
  10. Haagsma C. J., van Riel P. L., de Jong A. J., van de Putte L. B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997 Oct;36(10):1082–1088. doi: 10.1093/rheumatology/36.10.1082. [DOI] [PubMed] [Google Scholar]
  11. Haagsma C. J., van Riel P. L., de Rooij D. J., Vree T. B., Russel F. J., van't Hof M. A., van de Putte L. B. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol. 1994 Nov;33(11):1049–1055. doi: 10.1093/rheumatology/33.11.1049. [DOI] [PubMed] [Google Scholar]
  12. Hanrahan P. S., Russell A. S. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol. 1988 Jul;15(7):1078–1080. [PubMed] [Google Scholar]
  13. Joyce D. A., Will R. K., Hoffman D. M., Laing B., Blackbourn S. J. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991 Dec;50(12):913–914. doi: 10.1136/ard.50.12.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mooij P. N., Thomas C. M., Doesburg W. H., Eskes T. K. Multivitamin supplementation in oral contraceptive users. Contraception. 1991 Sep;44(3):277–288. doi: 10.1016/0010-7824(91)90018-b. [DOI] [PubMed] [Google Scholar]
  15. Morgan S. L., Baggott J. E., Lee J. Y., Alarcón G. S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998 Mar;25(3):441–446. [PubMed] [Google Scholar]
  16. Morgan S. L., Baggott J. E., Refsum H., Ueland P. M. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):547–556. doi: 10.1038/clpt.1991.180. [DOI] [PubMed] [Google Scholar]
  17. Morgan S. L., Baggott J. E., Vaughn W. H., Austin J. S., Veitch T. A., Lee J. Y., Koopman W. J., Krumdieck C. L., Alarcón G. S. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994 Dec 1;121(11):833–841. doi: 10.7326/0003-4819-121-11-199412010-00002. [DOI] [PubMed] [Google Scholar]
  18. Nesher G., Moore T. L. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum. 1990 Jul;33(7):954–959. doi: 10.1002/art.1780330706. [DOI] [PubMed] [Google Scholar]
  19. Refsum H., Helland S., Ueland P. M. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther. 1989 Nov;46(5):510–520. doi: 10.1038/clpt.1989.179. [DOI] [PubMed] [Google Scholar]
  20. Selhub J., Dhar G. J., Rosenberg I. H. Inhibition of folate enzymes by sulfasalazine. J Clin Invest. 1978 Jan;61(1):221–224. doi: 10.1172/JCI108921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shiroky J. B., Neville C., Esdaile J. M., Choquette D., Zummer M., Hazeltine M., Bykerk V., Kanji M., St-Pierre A., Robidoux L. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993 Jun;36(6):795–803. doi: 10.1002/art.1780360609. [DOI] [PubMed] [Google Scholar]
  22. Tishler M., Caspi D., Fishel B., Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988 Jul;31(7):906–908. doi: 10.1002/art.1780310712. [DOI] [PubMed] [Google Scholar]
  23. Weinblatt M. E., Maier A. L., Coblyn J. S. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol. 1993 Jun;20(6):950–952. [PubMed] [Google Scholar]
  24. te Poele-Pothoff M. T., van den Berg M., Franken D. G., Boers G. H., Jakobs C., de Kroon I. F., Eskes T. K., Trijbels J. M., Blom H. J. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem. 1995 Mar;32(Pt 2):218–220. doi: 10.1177/000456329503200218. [DOI] [PubMed] [Google Scholar]
  25. van der Heijde D. M., van 't Hof M. A., van Riel P. L., Theunisse L. A., Lubberts E. W., van Leeuwen M. A., van Rijswijk M. H., van de Putte L. B. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990 Nov;49(11):916–920. doi: 10.1136/ard.49.11.916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. van der Put N. M., Eskes T. K., Blom H. J. Is the common 677C-->T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. QJM. 1997 Feb;90(2):111–115. doi: 10.1093/qjmed/90.2.111. [DOI] [PubMed] [Google Scholar]
  27. van der Put N. M., Steegers-Theunissen R. P., Frosst P., Trijbels F. J., Eskes T. K., van den Heuvel L. P., Mariman E. C., den Heyer M., Rozen R., Blom H. J. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995 Oct 21;346(8982):1070–1071. doi: 10.1016/s0140-6736(95)91743-8. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES